Leica Biosystems Aperio Digital Pathology Now Nationwide Standard of Care in Kuwait*

Food and Healthcare Press Releases Tuesday May 23, 2017 15:15
VISTA, California--23 May--PRNewswire/InfoQuest

Leica Biosystems announced today that it has struck a key partnership with the Kuwait Ministry of Health, through its distributor, Technical Services Supplies Trading & Contracting Company, W.L.L. The Pathology Council of Kuwait will now adopt Leica Biosystems digital pathology as its standard of care. This initiative will create a nationwide pathology network, powered by Aperio ePathology Solutions , linking eight key hospitals and leveraging pathology expertise across the country.

(Photo: http://mma.prnewswire.com/media/515139/Leica_Biosystems_Aperio_ePathology.jpg )

"With one of the most extensive digital pathology initiatives in the world, Kuwait is leading the charge to transform pathology and its critical role in healthcare," said Jerome Clavel, Vice President and General Manager for Leica Biosystems Pathology Imaging. "Our Aperio ePathology Solutions will enable rapid sharing and collaboration. This will reduce the need for pathologists to travel and increase patient access especially in remote locations."

The Kuwait Cancer Control Center (KCCC) has been using Aperio ePathology since 2011, for both national and international slide sharing and collaboration. Building on their experience, the nationwide hub-and-spoke deployment of Aperio ePathology will enable efficient utilization of Kuwait's pathology expertise; providing pathologists with rapid access to slides and cases.

"The full adoption of Aperio ePathology throughout Kuwait is a critical, technological advancement for the pathology workflow. It will make secondary reviews and collaboration easier, faster and more efficient. In the past, shipping of glass slides required 3 to 4 days by itself. Now, subspecialty expertise can be available to remote locations within 24 hours without sending any physical slides," said Dr. Abdullah Akbar, Consultant Pathologist, Head of the Laboratory Medicine Department, Sabah Hospital, and Head of the Histopathology Committee, Ministry of Health. "Digital Pathology will help to improve turnaround times, and therefore give patients faster results."

*The clinical use claims described in the information provided have not been cleared or approved by the U.S. FDA nor are the products available in the United States.
About Leica Biosystems:

Leica Biosystems (LeicaBiosystems.com) is a global leader in workflow solutions and automation, integrating each step in the workflow. As the only company to own the workflow from biopsy to diagnosis, we are uniquely positioned to break down the barriers between each of these steps. Our mission of "Advancing Cancer Diagnostics, Improving Lives" is at the heart of our corporate culture. Our easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries and is headquartered in Nussloch, Germany.

Media Contact:
Kristin O'Neill
Manager, Global Brand Marketing
LBS-GlobalMarketing@leicabiosystems.com
+1-847-821-3537
Source: Leica Biosystems

Latest Press Release

ESMO Emphasises Importance of Cancer on Global Health Agenda at WHA

At the World Health Assembly in Geneva, ESMO delivered two statements positioning cancer as a priority on the WHO global agenda. (Photo: https://mma.prnewswire.com/media/696385/WHA_Global_Health_Agenda.jpg ) ESMO advocated the strengthening of health...

Real-World Evidence Shows Clinically Meaningful Weight Loss in People Receiving Saxenda(R)

People treated with Saxenda(R) (liraglutide 3 mg) for weight management lost an average of 8.1 kg after six months in a real-world clinical setting, in combination with diet and exercise. The data were presented this week at both the 25th European...

Venus Medtech#s strategic investment in Keystone Heart deepens the technical layout of cerebral embolic protection market

China Venus Medtech (Hangzhou) Inc. announced a partnership agreement for strategic investment and authorization with Keystone Heart. This agreement will grant Venus Medtech the right to exclusively develop, manufacture and sell the 3rd generation...

WCG (WIRB-Copernicus Group) Clinical Services Division Opens Office in Japan

WCG(TM) (WIRB-Copernicus Group(R)) Clinical Services Division, the world's leading provider of solutions that measurably improve the quality and efficiency of clinical research, today announced the opening of the company's new office in Tokyo, Japan....

Head-to-Head Trial Shows Refixia(R) Achieves Greater Total Factor IX Exposure in People With Haemophilia B Than Recombinant Factor IX-Fc Fusion Protein

Adults with haemophilia B who received a single dose Refixia(R) (nonacog beta pegol; N9-GP) achieved greater total factor IX exposure than those treated with rFIXFc (recombinant factor IX-Fc fusion protein). The head-to-head paradigm7 trial also observed...

Related Topics